Prime Medicine (NASDAQ:PRME) Stock Rating Lowered by Wall Street Zen

Prime Medicine (NASDAQ:PRME) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Prime Medicine in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Prime Medicine Price Performance

PRME opened at $3.81 on Friday. The firm’s 50 day moving average price is $5.00. Prime Medicine has a 52-week low of $1.11 and a 52-week high of $6.94. The stock has a market capitalization of $512.71 million, a price-to-earnings ratio of -2.65 and a beta of 2.64.

Prime Medicine (NASDAQ:PRME) last released its quarterly earnings results on Friday, November 7th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). Prime Medicine had a negative net margin of 3,301.64% and a negative return on equity of 184.47%. The firm had revenue of $1.23 million for the quarter.

About Prime Medicine

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology.